Journal
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
Volume 29, Issue 2, Pages 103-110Publisher
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-2008-1063849
Keywords
pulmonary Aspergillosis; voriconazole; aspergillus fumigatus
Categories
Ask authors/readers for more resources
As the population of patients with prolonged neutropenia, those receiving hematopoictic stem cell transplantation or lung transplantation, or those with human immunodeficiency virus or acquired immunodeficiency syndrome continues to increase, the rising incidence of pulmonary aspergillosis is unlikely to diminish. Aspergillus species are ubiquitous in nature, have no geographic predilection, and the spectrum of disease they cause is myriad, ranging from noninvasive disease with colonization to disseminated disease with an associated high mortality rate. The extent of disease is thus largely responsible for both the choice and the duration of antifungal therapy. Recent years have seen an expansion of antifungal agents, with efficacy against Aspergillus requiring an understanding of the full spectrum of disease for them to be used appropriately. Diagnosis is often difficult because existing tests lack desired sensitivity or specificity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available